• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe
Jeff Lombard

Jeff Lombard

,

[email protected]

Jeff Lombard is of counsel in the Palo Alto office of Gibson, Dunn & Crutcher and a member of the firm’s Securities Litigation Practice Group.

View Full Profile

Life Sciences Securities Litigation Insights: Even Marketing Materials Can Subject Issuers to Securities Fraud Claim

March 25, 2025 | Posted by Ryan A. Murr; Branden C. Berns; Jeff Lombard; Jessica Valenzuela; Brian M. Lutz; Craig Varnen; Monica K. Loseman Topic(s): Securities Litigation

Case Highlights:

On May 7, 2024, a federal district court dismissed securities fraud claims brought against a pharmaceutical company related to a marketing slogan used to promote the company’s drug.  At issue in Sneed v. AcelRx Pharms., Inc. (“Sneed”)[1], was AcelRx Pharmaceuticals, Inc.’s (“AcelRx”) marketing slogan, “Tongue and Done,” used to promote its FDA-approved drug DSUVIA, an opioid painkiller.  AcelRx had presented the “Tongue and Done” slogan on its website, among other places, to highlight the ease of administering DSUVIA (i.e., sublingually) compared to other opioid painkillers, which are administered either orally (which requires a patient’s ability to swallow) or via intravenous injection.

Read More

Executive Email Can Expose Public Companies to Securities Fraud Claim

December 20, 2024 | Posted by Branden C. Berns; Jeff Lombard; Topic(s): Securities Litigation

Pizzuto v. Homology Meds., Inc., No. 1:23-CV-10858, 2024 WL 1436025
(D. Mass. Mar. 31, 2024)

Case Highlight

In a securities fraud action earlier this year, an executive’s statement made in an email to a single research analyst was alleged to be false or misleading. In Pizzuto v. Homology Meds (“Pizzuto”), plaintiffs brought a securities class action complaint against Homology Medicines Inc. (“Homology”), a biopharmaceutical company, alleging that the company’s statements regarding the safety and efficacy of its gene therapy treatment were false and misleading.

Read More

Primary Sidebar

Gibson Dunn Life Sciences
2025 Outlook Webcast Series
Capital Markets: Click here to view the video recording and program materials.
Royalty Finance: Click here to view the video recording and program materials.
Read ROYALTY REPORT here.

Topics

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Updates

Securities Litigation

Shareholder Activism

Trends and Insights

Editors

Rachel Baron

Branden C. Berns

Lindsay Bernsen Wardlaw

Aaron K. Briggs

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Charlotte Jacobsen

Jin Hee Kim

Wynne Leahy

Jeff Lombard

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

James Moloney

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Jonathan Phillips

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Adam Smith

Karen A. Spindler

Eric J. Stock

Hong Tran

Todd J. Trattner

Stephen Weissman

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.